Results For "Enveric-Biosciences"

3 News Found

Enveric Biosciences bags key US patent for next-gen neuropsychiatric drugs

Biotech | January 01, 2026

Enveric Biosciences bags key US patent for next-gen neuropsychiatric drugs

The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”

Enveric Biosciences advances drug development for mental health indications

Biotech | July 16, 2022

Enveric Biosciences advances drug development for mental health indications

Advancing to IND-enabling studies with multiple drug candidates

Enveric clears FDA feedback milestone, prepares IND submission for EB-003

Clinical Trials | September 17, 2025

Enveric clears FDA feedback milestone, prepares IND submission for EB-003

IND application for EB-003 expected in early 2026

Latest Stories

INDIA-EU FTA unlocks access to $572.3 billion EU pharmaceuticals & medical devices market

Lubrizol showcases India manufacturing expansion at WHX Dubai

Will Forte joins Teva Pharmaceuticals to shine spotlight on Huntington’s disease

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging